2020
DOI: 10.1093/ecco-jcc/jjz203.648
|View full text |Cite
|
Sign up to set email alerts
|

P520 Association between ustekinumab trough levels and biomarkers in patients with Crohn’s disease

Abstract: Background Ustekinumab (UTK) is a human immunoglobulin (Ig) G1 kappa monoclonal antibody approved in 2017 for the treatment of Crohn’s Disease (CD). Up until now, there has not been enough evidence of the relationship between ustekinumab trough levels (UTL) and the clinical evolution and biological markers of the disease. Our study aimed to investigate the relationship between UTL and different biomarkers in a real-world setting. Methods … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…For ADA, maintenance levels of ≥ 7 μg/mL are associated with fistula healing, whereas levels ≥ 10 μg/mL are associated with complete fistula closure [63,64 ▪ ]. Additionally, a median IFX level of 5.5 μg/mL and median ADA level of 6.3 μg/mL has been associated with radiological response defined as a VAI of 7 or less [66]. No studies of UST/VDZ levels and pCD have been published yet.…”
Section: Medical Managementmentioning
confidence: 99%
“…For ADA, maintenance levels of ≥ 7 μg/mL are associated with fistula healing, whereas levels ≥ 10 μg/mL are associated with complete fistula closure [63,64 ▪ ]. Additionally, a median IFX level of 5.5 μg/mL and median ADA level of 6.3 μg/mL has been associated with radiological response defined as a VAI of 7 or less [66]. No studies of UST/VDZ levels and pCD have been published yet.…”
Section: Medical Managementmentioning
confidence: 99%